Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects

Objective: Pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity studies were conducted to evaluate the bioequivalence of CMAB807, a biosimilar to denosumab (Prolia(®)), which is the only approved RANKL inhibitor for the treatment of osteoporosis. Methods: In this randomized, doubl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hanjing, Chen, Weili, Yuan, Fei, Guo, Qingcheng, Zhang, Xunmin, Wang, Chenguang, Li, Xuening
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819684/
https://www.ncbi.nlm.nih.gov/pubmed/35140619
http://dx.doi.org/10.3389/fphar.2022.821944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819684/
https://www.ncbi.nlm.nih.gov/pubmed/35140619
http://dx.doi.org/10.3389/fphar.2022.821944

Ejemplares similares